Zhejiang Hengkang Deferasirox Zhejiang Hengkang Deferasirox

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"AustinPx","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"DisperSol and Catalent Collaborate to Establish KinetiSol\u00ae Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline","therapeuticArea":"Hematology","highestDevelopmentStatus":"Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Phase II"},{"orgOrder":0,"company":"Aucta Pharmaceuticals","sponsor":"Oakrum Pharma, LLC","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU\u00ae Sprinkle (Deferasirox Granules)","therapeuticArea":"Hematology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2021","url1":"","url2":"","graph1":"Hematology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Deferasirox

    Menu

    Deferasirox

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Aucta Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual BoothAucta is a global brand that creates better products from proven molecules.
              Contact Supplier Contact Supplier
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Oakrum Pharma and Aucta Pharma Announce U.S. FDA Approval of Generic Version of JADENU® Sprinkle (Deferasirox Granules)

              Details:

              JADENU (deferasirox) tablets for oral use and JADENU® Sprinkle (deferasirox) granules are indicated for the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.

              Lead Product(s): Deferasirox

              Therapeutic Area: Hematology Product Name: Jadenu

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oakrum Pharma, LLC

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 22, 2021

              Aucta Company Banner

              CPhI Worldwide, Milan

              Attending

              envelop Contact Supplier

              AustinPx

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              DisperSol and Catalent Collaborate to Establish KinetiSol® Technology Manufacturing Hub for DisperSol Pharmaceutical Pipeline

              Details:

              DisperSol’s active programs include, DST-0509 about to enter Phase 3 for iron overload disorder, DST-2970 in Phase 2 for refractory metastatic prostate cancer and DST-8294 for treatment of clotting disorders.

              Lead Product(s): Deferasirox

              Therapeutic Area: Hematology Product Name: DST-0509

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Catalent Pharma Solutions

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration August 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Synnat Deferasirox
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Close
              4
              Post Enquiry
              POST ENQUIRY